Sanofi profits 4.26 billion euros in the 3rd quarter with emphasis on Dupixent
French pharmaceutical company reports a 17.6% increase in adjusted profit at constant exchange rates, but the Times Brasil articles differ on one of the numbers.
BY THE X-TRADER NEWS NEWSROOM · REPORTING FROM TIMES BRASIL · 2 MIN
French pharmaceutical company Sanofi closed the third quarter of 2026 with adjusted net profit of €4.255 billion, according to Times Brasil. At constant exchange rates, the result represents an increase of 17.6% over the same period of the previous year. The balance sheet was released this Friday (30).
Net revenue reached €14.444 billion (R$88 billion), an increase of 14.3% at constant exchange rates. Adjusted operating profit totaled €5.430 billion (R$33 billion), 19.7% above the previous year, and the operating margin rose from 35.7% to 37.6%.
Per share, adjusted earnings per share (LPA) was €3.55 (R$22), an increase of 19.6% at constant exchange rates. Another report from the same newspaper reports that adjusted EPS grew 22%, also to €3.55, and that analysts consulted by FactSet expected €2.79. This text also points out that revenue rose 16.2% and exceeded the market forecast of €13.60 billion.
The highlight was Dupixent, the group's main medicine, whose sales increased 34.8%, to €5.69 billion at constant exchange rates. Revenues from new medicines rose 31.4% to €1.39 billion. There is, however, a divergence: one of the articles cites net profit of €3.02 billion, an increase of 7.8%, without informing whether the value is adjusted, a number very far from the €4.255 billion in the main text.
Constant exchange rate is the method that eliminates the effect of currency variations and shows the growth of operations. For the Brazilian reader, however, the value in reais depends on the euro exchange rate on the date of conversion, and the figures in reais cited by the newspaper follow this criterion.
What changes for the investor
For those who follow European pharmaceutical companies or have exposure to the euro, the balance brings two points of attention. The first is that the growth presented in constant exchange rates may be different from what appears in reais, which is why anyone investing with resources in reais must observe the conversion. The second is the divergence between the articles: the texts do not clarify the difference between profits of €4.255 billion and €3.02 billion, and it is worth checking the company's official statement before drawing conclusions. This analysis is not a buy or sell recommendation and does not project prices.
Automatically translated from Portuguese.
